PET imaging of tau protein targets: a methodology perspective

Brain Imaging and Behavior
Cristina LoisJulie C Price

Abstract

The two neuropathological hallmarks of Alzheimer's disease (AD) are amyloid-[Formula: see text] plaques and neurofibrillary tangles of tau protein. Fifteen years ago, Positron Emission Tomography (PET) with Pittsburgh Compound B (11C-PiB) enabled selective in-vivo visualization of amyloid-[Formula: see text] plaque deposits and has since provided valuable information about the role of amyloid-[Formula: see text] deposition in AD. The progression of tau deposition has been shown to be highly associated with neuronal loss, neurodegeneration, and cognitive decline. Until recently it was not possible to visualize tau deposition in-vivo, but several tau PET tracers are now available in different stages of clinical development. To date, no tau tracer has been approved by the Food and Drug Administration for use in the evaluation of AD or other tauopathies, despite very active research efforts. In this paper we review the recent developments in tau PET imaging with a focus on in-vivo findings in AD and discuss the challenges associated with tau tracer development, the status of development and validation of different tau tracers, and the clinical information these provide.

References

Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
Jan 1, 1990·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·H Braak, E Braak
Mar 1, 1969·Brain : a Journal of Neurology·M I Olson, C M Shaw
Jan 1, 1993·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·R E CarsonP Herscovitch
Jan 16, 2002·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Kooresh Shoghi-JadidJorge R Barrio
Mar 3, 2004·Annals of Neurology·William E KlunkBengt Långström
Jun 10, 2005·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Julie C PriceChester A Mathis
Feb 1, 2008·International Journal of Geriatric Psychiatry·Donald R Royall
Jul 12, 2008·Molecular Neurodegeneration·Fei Liu, Cheng-Xin Gong
Mar 19, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association
Oct 18, 2011·Journal of Neuropathology and Experimental Neurology·Heiko BraakKelly Del Tredici
Jan 24, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Bradley T HymanThomas J Montine
Dec 14, 2012·Journal of Alzheimer's Disease : JAD·David T ChienHartmuth C Kolb
Feb 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Chun-Fang XiaHartmuth C Kolb
Jul 17, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Nobuyuki OkamuraYukitsuka Kudo
Aug 21, 2013·Journal of Alzheimer's Disease : JAD·David T ChienHartmuth C Kolb
Nov 13, 2013·Nature Reviews. Neurology·Ezio Giacobini, Gabriel Gold
Mar 5, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·David A Drachman
Apr 1, 2014·Brain : a Journal of Neurology·Nobuyuki OkamuraVictor L Villemagne
Oct 29, 2014·Acta Neuropathologica·John F CraryPeter T Nelson
Dec 17, 2014·Lancet Neurology·Victor L VillemagneChristopher C Rowe
Jan 30, 2015·Acta Neuropathologica·Charles DuyckaertsToshiki Uchihara
Mar 21, 2015·Lancet Neurology·Michael T HenekaMarkus P Kummer
May 27, 2015·Nature Neuroscience·Karl Herrup
Jul 18, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Yasuyuki KimuraMakoto Higuchi
Sep 2, 2015·Bioorganic & Medicinal Chemistry Letters·Min WangQi-Huang Zheng
Oct 28, 2015·Annals of Neurology·Keith A JohnsonReisa Sperling
Oct 30, 2015·Physics in Medicine and Biology·Roger N GunnJulie C Price
Nov 7, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Ryuichi HaradaYukitsuka Kudo
Nov 18, 2015·European Journal of Nuclear Medicine and Molecular Imaging·M DaniP Edison
Jan 6, 2016·The British Journal of Psychiatry : the Journal of Mental Science·Judith R Harrison, Michael J Owen
Jan 12, 2016·Biomolecules·Ryuichi HaradaYukitsuka Kudo
Mar 5, 2016·Neuron·Michael SchöllWilliam J Jagust

❮ Previous
Next ❯

Citations

Feb 16, 2019·Acta Neuropathologica Communications·Santosh JadhavNorbert Zilka
Sep 25, 2020·European Journal of Nuclear Medicine and Molecular Imaging·Mona-Lisa MalarteLaetitia Lemoine
Jan 13, 2019·Molecular Psychiatry·Antoine LeuzyAgneta Nordberg
Jul 24, 2020·Scientific Reports·Holly C HunsbergerChristine Ann Denny
Oct 30, 2019·EJNMMI Radiopharmacy and Chemistry·Solveig TiepoltOsama Sabri
Jan 28, 2021·Journal of Medicinal Chemistry·Nerella Sridhar GoudPardeep Kumar
Feb 7, 2021·European Journal of Medicinal Chemistry·Daniela MalafaiaArtur M S Silva
Feb 17, 2021·Neurobiology of Aging·Gwenn S SmithClifford I Workman
May 15, 2021·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Grant RigneyAbass Alavi
Sep 15, 2018·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Susan M Landau
Jun 29, 2021·NeuroImage. Clinical·Matthew D ZammitBradley T Christian
Sep 29, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Claire SextonMaria C Carrillo
Oct 12, 2021·Journal of Proteome Research·Pablo San Segundo-AcostaRodrigo Barderas

❮ Previous
Next ❯

Software Mentioned

Piramal

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.